Discovery of <b>DN1679</b> as a Potent, Orally Bioavailable, and Highly Selective CDK12/13 Dual Degrader for the Treatment of Triple-Negative Breast Cancer
Year: 2025
Type: article
Language: en
Topic: Advanced Breast Cancer Therapies
Authors and affiliations:
raw_author_name: Danni Chen
raw_affiliation_strings: Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences
Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences
Zhejiang University
raw_author_name: Jiawen Hu
raw_affiliation_strings: Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences
Zhejiang University
raw_author_name: Yiling Yu
raw_affiliation_strings: Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences
Zhejiang University
raw_author_name: Kailin Li
raw_affiliation_strings: Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences
Zhejiang University
raw_author_name: Tingting Wang
raw_affiliation_strings: Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University
raw_author_name: Zidong Wang
raw_affiliation_strings: Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences
Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences
Zhejiang University
raw_author_name: Yi Yuan
raw_affiliation_strings: Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences
Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences
Zhejiang University
raw_author_name: Xuejing Shao
raw_affiliation_strings: Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences
Zhejiang University
raw_author_name: Meidan Ying
raw_affiliation_strings: Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences
Zhejiang University
raw_author_name: Bo Yang
raw_affiliation_strings: Hangzhou City University
Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University
Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences
School of Medicine
Zhejiang University
raw_author_name: Qiaojun He
raw_affiliation_strings: Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences
Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University
Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences
Zhejiang University
raw_author_name: Ji Cao
raw_affiliation_strings: Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University
Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences
Zhejiang University
raw_author_name: Li Jiang
raw_affiliation_strings: Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University
raw_author_name: Cheng-Liang Zhu
raw_affiliation_strings: Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences
Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences
Zhejiang University